Artivion

Artivion, Inc. focuses on developing solutions that address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment provides cardiac and vascular tissue preservation services. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Artivion reports strong revenue growth, FDA engagement on trial data

Artivion's Q4 2022 performance reflects solid revenue growth and improved margins, despite trial setbacks.
The company's strategic focus on innovation and expansion presents long-term growth opportunities.
Challenges with trial outcomes and FDA discussions highlight regulatory complexities impacting approvals.
Engagement with the FDA to address trial data issues could pave the way for future product launches.

Artivion (AORT) reports strong Q1 performance and eyes FDA approvals for growth

Artivion's Q1 performance showcases steady growth and strategic focus on product approvals and market expansion. Despite challenges in margins and debt, the company's outlook remains optimistic, with raised guidance for revenue and EBITDA. Key opportunities lie in FDA approvals and targeted growth in emerging markets.

Artivion excels in Q2 2023, raises revenue guidance for growth

Artivion's Q2 2023 performance reflects robust revenue growth, improved profitability, and enhanced cash position, setting the stage for future success.
The company's focus on innovation, clinical trials progress, and raised revenue guidance underscore its commitment to sustained growth and market leadership.
With strong financial fundamentals and a positive outlook for revenue and EBITDA, Artivion is well-positioned to capitalize on market opportunities and drive shareholder value.
Artivion's strategic initiatives and product advancements position it for continued success, supported by a solid financial foundation and a focus on operational efficiency.

Artivion reports robust Q3 results, eyes double-digit growth in 2024

Artivion's Q3 2023 performance was strong, with revenue growth and positive clinical data driving optimism for future growth and market share gains.
While challenges exist in balancing profitability and growth, the company's focus on top-line revenue growth and market expansion presents opportunities for sustained success.
With a clear roadmap for continued momentum in 2024, Artivion aims for double-digit revenue growth and $75 million EBITDA, supported by product innovation and market strategies.

Artivion reports robust 2023 growth, eyes market expansion and innovation

Artivion's strong financial performance in 2023, coupled with positive clinical trial results, sets a solid foundation for future growth.
The company's focus on innovation, market expansion, and optimized portfolio positions it well for continued success in 2024 and beyond.
Challenges with hemiarch procedures and the DANE connection underscore the importance of ongoing research and development efforts.
With a strategic approach to market growth and product development, Artivion is poised to capitalize on emerging opportunities and drive value for stakeholders.

Artivion reports robust Q1 performance, eyes growth in key markets

Artivion's Q1 2024 performance reflects strong revenue and EBITDA growth, driven by key product segments and regions. Positive clinical trial results and raised revenue guidance indicate a promising outlook. Challenges include regional revenue fluctuations and cash flow concerns.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artivion, Inc. engages in the research and development of solutions which address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Artivion (AORT) Reports Q3 Loss, Tops Revenue Estimates

Third Quarter and Recent Business Highlights: Achieved revenue of $76.8 million in the third quarter of 2022 versus $72.2 million in the third quarter of 2021, an increase of 6% on a GAAP basis and 11% on a non-GAAP constant currency basis On-X revenues increased 17% on a GAAP basis and 19% on a non-GAAP constant currency basis in the third quarter of 2022 compared to the third quarter of 2021 ATLANTA , Nov. 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the third quarter ended September 30, 2022. "We remain well positioned to deliver on our growth strategy, particularly given the continued fundamental strength of our business.

Artivion Reports Third Quarter 2022 Financial Results

ATLANTA , Oct. 20, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results will be released on Thursday, November 3, 2022 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2022 Financial Results

ATLANTA , Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A.

Elizabeth Hoff Joins Artivion Board of Directors

Artivion, Inc.'s decision to pull the PROACT Xa trial resulted in heavy downside for the share price. Investors have sold positions rapidly such that the stock trades at multi-year lows.

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, Sept. 23, 2022 /PRNewswire/ --- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin.

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

ATLANTA , Sept. 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deutsche Bank 30th Annual Leveraged Finance Conference on Wednesday, September 21, 2022.

Artivion to Present at the Deutsche Bank 30th Annual Leveraged Finance Conference

Artivion, Inc. (NYSE:AORT ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group James Mackin - Chairman, President & CEO David Lee - EVP, COO & CFO Conference Call Participants Frederick Wise - Stifel, Nicolaus & Company Suraj Kalia - Oppenheimer Operator Greetings, and welcome to the Artivion Second Quarter 2022 Financial Results Conference Call. [Operator Instructions].

Artivion, Inc. (AORT) CEO James Mackin on Q2 2022 Results - Earnings Call Transcript

ATLANTA , Aug. 4, 2022 /PRNewswire/ --  Second Quarter and Recent Business Highlights: Achieved revenue of $80.3 million in the second quarter 2022 versus $76.1 million in the second quarter of 2021, an increase of 6% on a GAAP basis and 9% on a non-GAAP constant currency basis Enrolled first patients in U.S. AMDS clinical trial, PERSEVERE Completed on-site facility inspections for BioGlue CE Mark renewal Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the second quarter ended June 30, 2022. "During the second quarter we made substantial progress on each of our key three-year strategic growth initiatives.

Artivion Reports Second Quarter 2022 Financial Results

Artivion (AORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Artivion (AORT) a New Buy Stock

Study Designed to Evaluate the Safety and Efficacy of the AMDS Hybrid Prosthesis to Treat Acute DeBakey Type I Aortic Dissections & Support U.S. FDA PMA Submission ATLANTA , July 27, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has initiated enrollment in the PERSEVERE clinical trial to determine if patients with an acute DeBakey Type I aortic dissection can be treated safely and effectively using the AMDS Hybrid Prosthesis. The trial is designed to support the company's forthcoming application to the U.S. Food and Drug Administration (FDA) for premarket approval of the AMDS.

Artivion Initiates Enrollment in PERSEVERE Clinical Trial

ATLANTA , July 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2022 financial results will be released on Thursday, August 4, 2022 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2022 Financial Results

Artivion (AORT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Artivion (AORT) Soars 10.2%: Is Further Upside Left in the Stock?

ATLANTA , May 16, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in the upcoming UBS 2022 Global Healthcare Conference on Monday, May 23, 2022 at the Lotte New York Palace.  The Company's fireside chat is scheduled to begin at 2:45 p.m.

Artivion to Participate in the UBS 2022 Global Healthcare Conference

Artivion, Inc. (NYSE:AORT ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Brian Johnston - Investor Relations Pat Mackin - Chief Executive Officer Ashley Lee - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Suraj Kalia - Oppenheimer Operator Greetings and welcome to the Artivion First Quarter 2022 Financial Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Artivion, Inc. (AORT) CEO Pat Mackin on Q1 2022 Results - Earnings Call Transcript

Achieved revenue of $77.2 million in the first quarter 2022 versus $71.1 million in the first quarter of 2021, an increase of 8.6% on a GAAP basis and 11.2% on a non-GAAP constant currency basis ATLANTA , May 5, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the first quarter ended March 31, 2022. "In the first quarter we made great progress on our recently unveiled three-year strategic growth initiatives announced at our analyst and investor day on March 23 rd.

Artivion Reports First Quarter 2022 Financial Results

ATLANTA, April 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022 financial results will be released on Thursday, May 5, 2022 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

ArtivionAnnounces Release Date and Teleconference Call Details for First Quarter 2022 Financial Results

ATLANTA, March 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming 21st Annual Needham Virtual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 9:30 a.m.

Artivion to Participate in the 21st Annual Needham Virtual Healthcare Conference

ATLANTA, March 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today published its inaugural Corporate Responsibility Report detailing the company's Environmental, Social, and Governance (ESG) initiatives. Artivion's 2022 Corporate Responsibility Report details several of the company's ESG efforts, including: Environmental initiatives to drive sustainability and limit Artivion's carbon footprint, including a disclosure relative to the Task Force on Climate-Related Financial Disclosures; Diversity, equity, and inclusion initiatives to create a welcoming and empowering workplace for every member of the global team as they strive to fulfill Artivion's mission to make leading-edge aortic technologies available to patients around the world; and Board of Directors ("Board") level initiatives to enhance Board and workforce diversity, Board refreshment, and Board oversight of the company's ESG initiatives, including human capital management.

Artivion Publishes Inaugural Corporate Responsibility Report

ATLANTA, March 9, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will host an Investor & Analyst Day in New York City on Wednesday, March 23, 2022 at 9:00 AM ET. The event will include presentations by members of management and cardiac and vascular surgeons who focus on treating patients with aortic disease.

Artivion to Host Investor & Analyst Day on March 23, 2022

ATLANTA, March 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 32nd Annual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 2:40 p.m.

Artivion to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Artivion, Inc. (AORT) CEO J. Patrick Mackin on Q4 2021 Results - Earnings Call Transcript

Artivion (AORT) delivered earnings and revenue surprises of 100% and 1.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Artivion (AORT) Reports Break-Even Earnings for Q4

ATLANTA, Feb. 17, 2022 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Achieved record revenue of $79.4 million in the fourth quarter 2021 versus $67.9 million in the fourth quarter of 2020, an increase of 16.9% on a GAAP basis and 18.8 % on a non-GAAP proforma constant currency basis Received FDA approval to launch enrollment in AMDS clinical trial Filed PMA with FDA for US PerClot Approval in October 2021 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the fourth quarter and full year ended December 31, 2021. "In the fourth quarter we achieved record quarterly revenues, driven by our aortic stent grafts and continued strength in our US On-X aortic valve business.

Artivion Reports Fourth Quarter and Full Year 2021 Financial Results

Artivion (AORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Artivion Stock (AORT)